Continuous Infusion Interleukin-2 and Famotidine in Metastatic Kidney Cancer

Quan, Walter; Vinogradov, Mikhail; Quan, Francine M.; Khan, Nawazish A.; Liles, Darla; Walker, Paul R.

doi:10.1089/cbr.2006.21.515

Cited by 3 publications

(2 citation statements)

References 23 publications

(32 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…and 20 mg famotidine i.v. twice a day) in patients with metastatic RCC suggests some benefit of the combination but the results are not conclusive or significant, probably due to the small number of patients recruited 254–258 …”

Section: Histamine As An Adjuvant To Cancer Immunotherapymentioning

confidence: 98%

Histamine in cancer immunology and immunotherapy. Current status and new perspectives

Sarasola

Delgado

Nicoud

et al. 2021

Pharmacology Res & Perspec

View full text Add to dashboard Cite

Cancer is the second leading cause of death globally and its incidence and mortality are rapidly increasing worldwide. The dynamic interaction of immune cells and tumor cells determines the clinical outcome of cancer. Immunotherapy comes to the forefront of cancer treatments, resulting in impressive and durable responses but only in a fraction of patients. Thus, understanding the characteristics and profiles of immune cells in the tumor microenvironment (TME) is a necessary step to move forward in the design of new immunomodulatory strategies that can boost the immune system to fight cancer. Histamine produces a complex and fine‐tuned regulation of the phenotype and functions of the different immune cells, participating in multiple regulatory responses of the innate and adaptive immunity. Considering the important actions of histamine‐producing immune cells in the TME, in this review we first address the most important immunomodulatory roles of histamine and histamine receptors in the context of cancer development and progression. In addition, this review highlights the current progress and foundational developments in the field of cancer immunotherapy in combination with histamine and pharmacological compounds targeting histamine receptors.

show abstract

Section: Histamine As An Adjuvant To Cancer Immunotherapymentioning

confidence: 98%

Histamine in cancer immunology and immunotherapy. Current status and new perspectives

Sarasola

Delgado

Nicoud

et al. 2021

Pharmacology Res & Perspec

View full text Add to dashboard Cite

show abstract

“…Quan and others 40 examined the addition of famotidine to IL-2 for treatment of 15 patients with metastatic RCC. Famotidine may augment LAK activity against kidney cancer cells.…”

Section: Interferon and Il-2 Combination Regimensmentioning

confidence: 99%

Current status of cytokine therapy in management of patients with metastatic renal cell carcinoma

Kapoor

Hotte

2012

CUAJ

View full text Add to dashboard Cite

Studies examining the efficacy of immunotherapy have used a variety of end points such as response rate (RR), complete response (CR) or partial response (PR); rate of progression; and progression-free and median survival. However, these studies used different definitions of these end points and none was blinded.5 Further, RR has been reported to be an unreliable surrogate of survival. 5A meta-analysis 7 of 1042 patients found that the overall proportion of responses (CR and PR) to interferon-α was 12%. CRs were quite rare. Favourable characteristics of responders included patients with prior nephrectomy and patients with lung metastases. In this particular patient population, the proportion of objective responses was as high as 44%. 7 The average time from the start of treatment to an objective response was about 3-4 months. Metastases of the central nervous system tended not to respond to interferon, and soft-tissue disease tended to respond more readily than bony metastases. Results of a review of more than 1500 patients 8 suggest that the disease RR is between 12% and 15% for patients receiving interferon-α. CRs occurred in 2%-5% patients, usually in those with pulmonary metastases. The recently published Cochrane collaboration review 5 estimated a gain of 3.8 months and a 1-year risk of mortality reduction by 44% for patients randomized to interferon-α2a, compared with patients randomized to control arms. Toxicity with interferon-α includes fever, malaise, flulike symptoms and night sweats, and is markedly less than that with interleukin-2 (IL-2). S28 REVIEW AbstractCytokine therapy with interferon-α and interleukin-2 has arguably been the standard treatment for patients with metastatic renal cell carcinoma for more than 20 years. In this paper, the current evidence for the use of cytokine therapy in this patient population is discussed, including the significant toxicity associated with these agents. A low overall response rate and a marginal survival advantage are observed with interferon-α and interleukin-2; however, these therapies have significant toxicity and impair quality of life. Unlike the current tyrosine-kinase inhibitors, complete tumour responses may be seen with interleukin-2, but again this therapy has significant morbidity and mortality. Newer anti-angiogenesis agents may be combined with current standard cytokine therapy for patients with metastatic renal cell carcinoma.

show abstract

Immunotherapy as a potential treatment approach for currently incurable bone metastasis

et al. 2023

View full text Add to dashboard Cite

Continuous Infusion Interleukin-2 and Famotidine in Metastatic Kidney Cancer

Cited by 3 publications

References 23 publications

Histamine in cancer immunology and immunotherapy. Current status and new perspectives

Histamine in cancer immunology and immunotherapy. Current status and new perspectives

Current status of cytokine therapy in management of patients with metastatic renal cell carcinoma

Immunotherapy as a potential treatment approach for currently incurable bone metastasis

Contact Info

Product

Resources

About